Loading...
Market
What will be the main challenge in scaling photosynthetic animal cells by 2025?
2
Resolution / Starting Odds
Cost • 25%
Efficiency • 25%
Regulation • 25%
Public acceptance • 25%
Scientific publications or industry reports
Story
Japanese Team Develops Photosynthetic Animal Cells in Chinese Hamster Ovary Cells Using Algal Chloroplasts
Nov 14, 2024, 01:07 AM
A Japanese research team has developed a groundbreaking technique that enables animal cells to perform photosynthesis by inserting chloroplasts isolated from red algae into Chinese Hamster Ovary cells. This innovative approach, which confirms the functionality of photosystem II in the implanted chloroplasts, holds the potential to revolutionize sustainable energy production and the creation of artificial meat and organs. The successful cultivation of these photosynthetic animal cells marks a significant advancement in biotechnology, with implications for environmental sustainability and food production.
View original story
Similar markets
Cost • 25%
Durability • 25%
Regulatory hurdles • 25%
Consumer acceptance • 25%
Scalability • 25%
Biocompatibility • 25%
Energy density • 25%
Cost • 25%
Immune rejection • 25%
Infection risk • 25%
Ethical concerns • 25%
Supply chain issues • 25%
Genome editing accuracy • 25%
Embryo implantation success • 25%
Viability of living specimens • 25%
Public opposition or regulatory issues • 25%
Efficiency improvement • 25%
Cost reduction • 25%
Durability enhancement • 25%
Other breakthrough • 25%
Scalability • 25%
Cost • 25%
Accuracy • 25%
Integration with existing systems • 25%
Improved gene editing techniques • 25%
New animal species used • 25%
Breakthrough in immunosuppressive drugs • 25%
Other significant advancement • 25%
Transmission Line Issues • 25%
Solar Panel Efficiency • 25%
Subsea Cable Installation • 25%
Other • 25%
US export restrictions • 25%
Technical issues with SMIC's N+2 process • 25%
Supply chain disruptions • 25%
Other reasons • 25%
Technical issues • 25%
Regulatory hurdles • 25%
Funding shortages • 25%
Market competition • 25%
Approval for clinical trials in the US • 25%
Approval for clinical trials in Europe • 25%
Successful treatment of another patient • 25%
No major milestone achieved • 25%